Trailing-twelve-month (TTM) revenue is $4.49 Billion with a year-over-year growth of +4.93%. Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-28 | $1,083,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-10-31 |
| Q4 FY2025Period ended 2025-12-28 | $1,160,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-12 |
| Q1 FY2026Period ended 2026-03-29 | $1,091,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-04 |
| Q2 FY2026Period ended 2026-06-28 | $1,159,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-07-31 |
| TTM revenue | $4,493,000,000 |
Current P/S: $41,310,952,000 market capitalization ÷ $4,493,000,000 TTM revenue = 9.19x.
Market capitalization source: FMP quote. Quote observed 2026-10-02T20:00:01.000Z. Latest revenue period ended 2026-06-28.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-28): $1.16B.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-10-02T21:35:37.995Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-01.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-28 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2025-12-28 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20192019-12-29 · USD | FY20202021-01-03 · USD | FY20212022-01-02 · USD | FY20222023-01-01 · USD | FY20232023-12-31 · USD | FY20252025-12-28 · USD |
|---|---|---|---|---|---|---|
| Microarray | N/A | N/A | $417M | $413M | $392M | $358M |
| Product | $802M | $788M | N/A |
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202021-01-03 · USD | FY20212022-01-02 · USD | FY20222023-01-01 · USD | FY20232023-12-31 · USD | FY20242024-12-29 · USD | FY20252025-12-28 · USD |
|---|---|---|---|---|---|---|
| Americas | $1.7B | $2.4B | $2.5B | $2.5B | $2.4B | $2.4B |
| Asia Pacific | $267M | $377M | $418M | $459M |
$4.49B
$4.49 Billion
+4.93%
vs. $4.28B a year ago (TTM)
+5.04%
5 Year compound annual growth rate
1 Year
+4.93%
3 Year
+0.32%
5 Year
+5.04%
10 Year
+6.98%
15 Year
+10.41%
20 Year
+21.49%
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $4.34B | ($34.00M) | (0.78%) |
| 2024 | $4.37B | ($132.00M) | (2.93%) |
| 2023 | $4.50B | ($80.00M) | (1.75%) |
| 2022 | $4.58B | +$58.00M | +1.28% |
| 2021 | $4.53B | +$1.29B | +39.73% |
| 2020 |
TTM Growth
+4.93%
3-Year CAGR
+0.32%
5-Year CAGR
+5.04%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-10-02T21:35:37.995Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-01.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
| N/A |
| N/A |
| Sequencing | N/A | N/A | $4.1B | $4.2B | $4.1B | $4.0B |
|---|
| Service, Other | $240M | $220M | N/A | N/A | N/A | N/A |
|---|
| $430M |
| CHINA | $342M | $502M | $472M | $384M | $308M | $243M |
|---|
| EMEA | $886M | $1.3B | $1.2B | $1.1B | $1.2B | $1.3B |
|---|
| $3.24B |
| ($304.00M) |
| (8.58%) |
| 2019 | $3.54B | +$210.00M | +6.30% |
| 2018 | $3.33B | +$581.00M | +21.11% |
| 2017 | $2.75B | +$353.63M | +14.74% |
| 2016 | $2.40B | +$178.61M | +8.05% |
